Results for tag: "Calciphylaxis"

Calciphylaxis is a rare, life-threatening condition that affects the small blood vessels of the skin and other organs, primarily in patients with end-stage renal disease or chronic liver disease. It is characterized by painful, necrotic skin lesions that can lead to sepsis and death. Treatment of calciphylaxis is challenging and involves aggressive wound care, antibiotics, and anticoagulants. In addition, drugs used to treat liver and kidney disorders, such as ursodeoxycholic acid, cinacalcet, and sodium thiosulfate, have been used to reduce calcium levels in the blood and improve calciphylaxis symptoms. The calciphylaxis market is a small but growing segment of the larger liver and kidney disorders drugs market. It is driven by the increasing prevalence of end-stage renal disease and chronic liver disease, as well as the need for more effective treatments for calciphylaxis. Some companies in the calciphylaxis market include AbbVie, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more